362 related articles for article (PubMed ID: 36071839)
1. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights.
Tian X; Yan T; Liu F; Liu Q; Zhao J; Xiong H; Jiang S
Front Pharmacol; 2022; 13():991052. PubMed ID: 36071839
[TBL] [Abstract][Full Text] [Related]
2. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma.
Chen S; Du Y; Guan XY; Yan Q
Front Oncol; 2023; 13():1204513. PubMed ID: 37576900
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Delivery of MnO
Chang CC; Dinh TK; Lee YA; Wang FN; Sung YC; Yu PL; Chiu SC; Shih YC; Wu CY; Huang YD; Wang J; Lu TT; Wan D; Chen Y
ACS Appl Mater Interfaces; 2020 Oct; 12(40):44407-44419. PubMed ID: 32865389
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.
Zeng Z; Lu Q; Liu Y; Zhao J; Zhang Q; Hu L; Shi Z; Tu Y; Xiao Z; Xu Q; Huang D
Front Oncol; 2021; 11():641522. PubMed ID: 34307125
[TBL] [Abstract][Full Text] [Related]
7. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Chen Z; Yuan T; Yan F; Ye S; Xie Q; Zhang B; Lin N; He Q; Yang B; Zhu H
BMC Cancer; 2022 Apr; 22(1):425. PubMed ID: 35440025
[TBL] [Abstract][Full Text] [Related]
8. DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Chen X; Yang G; Guo X; Zhang J; Sun W; Liu D; Wang H; Liu S
Oxid Med Cell Longev; 2022; 2022():2543220. PubMed ID: 35770048
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma.
Xu W; Yang M; Zhang W; Jia W; Zhang H; Zhang Y
Mater Today Bio; 2024 Feb; 24():100902. PubMed ID: 38188646
[TBL] [Abstract][Full Text] [Related]
11. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
13. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
Tang W; Chen Z; Zhang W; Cheng Y; Zhang B; Wu F; Wang Q; Wang S; Rong D; Reiter FP; De Toni EN; Wang X
Signal Transduct Target Ther; 2020 Jun; 5(1):87. PubMed ID: 32532960
[TBL] [Abstract][Full Text] [Related]
14. KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells.
Zhang J; Zhao X; Ma X; Yuan Z; Hu M
Int J Mol Med; 2020 Nov; 46(5):1794-1804. PubMed ID: 33000204
[TBL] [Abstract][Full Text] [Related]
15. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
[TBL] [Abstract][Full Text] [Related]
16. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment.
Wang Y; Wang Z; Jia F; Xu Q; Shu Z; Deng J; Li A; Yu M; Yu Z
Bioact Mater; 2022 Nov; 17():147-161. PubMed ID: 35386453
[TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
18. Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect.
Tian H; Zhu X; Lv Y; Jiao Y; Wang G
Cancer Manag Res; 2020; 12():5957-5974. PubMed ID: 32765096
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
20. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
